Alkermes made a pretax loss of $72.6 million (€66.8m) in the three months to the end of March 2017. That represents a decrease of 5.75 per cent on the(...)
Executives at Irish-headquartered biopharma group Alkermes received lower overall remuneration last year.
The group, which is domiciled in Ireland fo(...)
Biopharma group Alkermes has reported a sharp increase in its net loss in the first quarter on the back of increased investment in its late-stage pipe(...)
Revenue at Irish drug group Alkermes jumped almost 24 per cent in the first three months of the year, to $161.2 million, ahead of analyst expectations(...)
Alkermes, the company that acquired Elan Drug Technologies, yesterday reported “robust” results for what it called a “remarkable year”.
Connect with The Irish Times